Azunol Ointment 0.033% for skin inflammation (dimethyl isopropylazulene, guaiazulene, Azulon)

General information on Japanese Azunol Ointment 0.033% for skin inflammation (dimethyl isopropylazulene, guaiazulene, Azulon)

Package details: 10 tubes * 20 g

Manufacturer: Nippon Shinyaku Co., Inc., Japan

Active ingredients: dimethyl isopropylazulene (chemical formula C15H18)

Medical effect: Azunol ointment is effective for the treatment of eczema, dermal erosion and ulcer due to burn and other diseases.

Contraindications and precautions: do not use for pregnant or breastfeeding women. If an allergic reaction occurs, stop using the medicine and consult with your doctor. If you’re taking any other medication or receiving any other treatment, you have to consult with your doctor before use.

Dosage and administration

Apply adequate amount of the medicine several times a day according to the prescription of your doctor.

If the medicine gets into the eye, wash away with water. If the irritation appears, consult with the doctor immediately.

In any case, the doctor in charge may adjust the dosage according to the disease, age or symptoms.

How effective is Azunol Ointment 0.033% from Japan for skin inflammation (dimethyl isopropylazulene, guaiazulene, Azulon)?

Azunol onitment’s active ingredient is a dimethyl isopropylazulene, a derivative of azulene and a bicyclic sesquiterpene. It provides anti-allergic and anti-inflammatory effects and promotes wound healing by increasing the proliferation of the fibroblasts (M. Guarrera, L. Turbino, A. Rebora. “The Anti-Inflammatory Activity of Azulene”. Journal of the European Academy of Dermatology and Venereology, 2001, 15: 486–487).

Who should use Azunol Ointment 0.033% from Japan?

Azunol ointment is effective for the treatment of eczema, dermal erosion and ulcer due to burn and other diseases. Japanese doctors also use this medication for the acute skin symptoms in patients with cancer and anorexia nervosa (N. Ishiguro, M. Kawashima. “Striaelike epidermal distension: a newly recognized cutaneous manifestation in acute leg edema”. Archives of dermatology, 2002, 138(5): 641-2).